Drugs / 4-peptide vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00938223 Comparator | Aug 2000 → Nov 2003 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-peptide vaccine | “4-peptide vaccine” NCT00938223 ↗ |
| Modality | Vaccine | “This is an open-label, phase II study of a vaccine comprising melanoma peptides and a tetanus helper peptide” NCT00938223 ↗ |